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Setting: Quaternary pediatric hospital (Saint Louis Children’s Hospital) NICU and PICU.
Patients:
Infants <6
270.6 (hyperammonemia).
Edited by:
Jan Hau Lee,
KK Women’s and Children’s
Hospital, Singapore
Reviewed by:
Ramachandran Rameshkumar,
Jawaharlal Institute of Postgraduate
Medical Education and Research
(JIPMER), India
Esther Huimin Leow,
KK Women’s and Children’s
Hospital, Singapore
*Correspondence:
Kenneth E. Remy
kremy@wustl.edu
Specialty section:
This article was submitted to
Pediatric Critical Care,
a section of the journal
Frontiers in Pediatrics
Received: 29 June 2021
Accepted: 07 October 2021
Published: 05 November 2021
Citation:
Markham C, Williams C, Miller C,
Grange DK, Davis TK and Remy KE
(2021) Continuous Renal
Replacement Therapy for Two
Neonates With Hyperammonemia.
Front. Pediatr. 9:732354.
doi: 10.3389/fped.2021.732354

Frontiers in Pediatrics | www.frontiersin.org

months

of

age

with

an

ICD-9

diagnosis

of

Interventions: Continuous renal replacement therapy (CRRT).
Measurements and Main Results: We measure serum ammonia levels over time and
the rate of ammonia clearance over time. Continuous renal replacement therapy was
more effective than scavenger therapy alone (AmmonulTM ) for rapid removal of ammonia
in low weight infants (as low as 2.5 kg).
Conclusions: Continuous renal replacement therapy is technically feasible in low weight
infants with severe hyperammonemia secondary to an inborn error of metabolism.
Keywords: hyperammonemia, hemodialysis, neonate, citrullinemia, methylmalonic acidemia

INTRODUCTION
Pediatric inborn errors of metabolism that cause hyperammonemia pose specific technical
challenges in critical care management, especially in the newborn period when presenting in
extremis. During this newborn period, both urea cycle defects (UCDs) or organic acidemias
commonly present with hyperammonemia. Additionally, to a lesser extent, some patients with
maple syrup urine disease and fatty acid oxidation disorders can also have mildly elevated
ammonia. Infants with these aforementioned diseases commonly present with decreased levels of
consciousness and poor feeding, while up to 50% can also present with seizures (1). Appropriate
and prompt therapy is paramount to improved morbidity and mortality outcomes.
The ammonia scavenging agent sodium acetate and sodium phenylbutyrate (AmmonulTM ) has
been successful in improving outcomes for this patient population. Previous reports by Enns
et al. show improved survival of up to 84% in children with hyperammonemia—a staggering
improvement when directly compared to the 84% mortality that Nasogne et al. reported during the
same time period for patients that did not receive sodium acetate and sodium phenylbutyrate (2, 3).
Despite the improved outcomes achieved with ammonia scavenging therapy, mortality for neonates
with severely elevated serum ammonia remains high. Subgroup analysis of the Enns cohort shows
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that neonates with ammonia levels >1,000 µmol/L (1,804 µg/dl)
at presentation have a survival rate of <50% (3).
For neonates with severe UCDs or other in-born errors of
metabolism, continuous renal replacement therapies (CRRT)
including hemofiltration may be beneficial. Unfortunately, the
use of hemodialysis for newborns with hyperammonemia is
technically difficult due to vascular access and the extracorporeal
circuit volume which is large in proportion to an infant’s
circulating blood volume of 75–90 ml/kg. Additionally, RRT
requires high blood flow and dialysate rates (in ml/min)
that have the potential to cause circulatory collapse and/or
cardiac arrest. Hemodialysis alone is often associated with
rebound hyperammonemia (4). Consequently, practitioners have
considered other modes of dialysis and found that using
CRRT with increased blood flow and dialysate flow can be
effective (4, 5).
With careful considerations given to obtaining vascular
access and maintaining adequate hemodynamic support,
renal replacement therapy can be effective even for low
birth weight infants. Our aim with this study is to assess
the feasibility of CRRT in infants presenting with severe
hyperammonemia. We hypothesize that dialysis is an effective
method for ammonia clearance in this patient population
and careful consideration for its deployment may impact
overall outcomes.

TABLE 1 | Patient demographics and initial laboratory values.

Age
Gender

Patient B

4 days

3 days

F

M

Weight (kg)

2.52

2.92

Body surface area

0.19

0.2

Lactate

4.7

NA

Sodium

154

151

Potassium

4.9

4.4

Chloride

125

118

Bicarbonate (CO2 )

15

<5

Urea nitrogen

9

29

AST

61

241

ALT

24

41

Creatinine

1.5

0.7

Total calcium

6.3

7.1

Case A
Presentation
A 4 day old, Indian-American female that initially presented to
an outside emergency department for poor feeding and grunting.
Upon arrival to the ED, the patient was “sluggish,” hypothermic
to 35.5◦ C, and noted to have hypoxemia with SpO2 <90%. A
point of care (POC) glucose was <1.11 mmol/L. The patient
was given a bolus of D10 and D5 normal saline (NS) with
a repeat blood glucose value 1 h later of 3.5 mmol/L. Blood
cultures, complete blood count (CBC), and electrolyte panel were
collected with a significant finding of a white blood cell (WBC)
of 19.1 k/cumm. En route to the ED, the patient required bag
mask positive pressure ventilation for shallow respirations and
persistent hypoxemia. With signs of poor perfusion, posturing,
and apnea the patient was promptly intubated. After intubation,
she was hypotensive (30/20), requiring an additional 20 ml/kg NS
fluid bolus. Additionally, she was given phenobarbital (20 mg/kg)
for rhythmic tonic-clonic movements concerning for seizures.
Given findings of hypoxemia, hypotension, new seizure disorder,
hypoglycemia, and hypothermia, neonatal sepsis was considered
with ampicillin and cefotaxime antibiotics and acyclovir given
in the ED. The patient was promptly transported to the
pediatric intensive care unit (PICU) and noted to have significant
ammonia and lactate (1,382 µg/dl and 4.4 mmol/L, respectively)
levels. Other notable labs include aspartate transaminase (AST)
of 61 units/L and alanine transaminase (ALT) of 24 units/L.
Given a concern for an inborn error of metabolism, general
surgery was consulted and placed an emergent dialysis catheter
at the bedside. A 7 French apheresis catheter was placed in the
right internal jugular vein with a venous cut down approach.
Prior to catheter placement, vital signs were significant for: HR
209, RR 40 (intubated, sedated, on neuromuscular blockade), T
36.1◦ C, BP 94/67, SpO2 94% on 2 epinephrine infusion (up to
0.1 mcg/kg/min) and given calcium gluconate boluses of 100
mg/kg secondary to hemodynamic instability after central line
placement but prior to CRRT initiation.

METHODS
We conducted a retrospective cohort study in children
admitted from 2009 to 2015 presenting with emergencies from
inborn errors of metabolism at a single center, quaternary
pediatric hospital. Local IRB approved the study design and
waived the need to obtain informed consent (Washington
University IRB# 201506089). Patients were enrolled with the
following inclusion criteria: hospitalized infants <6 months
of age AND a diagnosis of hyperammonemia secondary to
an inborn error of metabolism, AND who received CRRT
for ammonia reduction. We excluded any patients who
received prior HD or who had CRRT for reasons other than
ammonia clearance.
The initial database screen was performed by one study
investigator who queried the hospital’s billing database for an
ICD-9 code of 270.6 (hyperammonemia). This initial screen was
further narrowed by two separate investigators who identified
patients that met enrollment criteria for the study. Descriptive
data is presented in each case as available in the electronic
medical record.

RESULTS
From 2009 to 2015, there were 138 inpatients with an ICD-9
coding diagnosis of hyperammonemia. Of those 138 patients,
six received CRRT during their hospital course and two met
inclusion criteria. All patient exclusions occurred as patients
were >6 months of age. Clinical data include demographic and
relevant laboratory data are summarized in Table 1.
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Technical Considerations

response to stimulation and did not exhibit a suck reflex. An
umbilical arterial catheter and double lumen umbilical venous
catheter were placed shortly after admission and 10% dextrose
containing fluids were started at a GIR of 7 mg/kg/min. Initial
laboratory screens included an ammonia of 623 µg/dl, ALT of
41 units/L, AST of 241 units/L, and an arterial blood gas with
pH of 7.06, PaCO2 of 13 mmHg, PaO2 of 151 mmHg, and base
deficit of 26.5 mEq/L. Surgery was consulted for vascular dialysis
catheter placement in the operating room; a 7 French apheresis
catheter was placed in his right internal jugular vein using
a venous cut down approach without complications. Prior to
hemodialysis catheter placement, he received Ammonul loading
dose of 720 mg (246 mg/kg) followed by a continuous infusion of
10.4 mg/kg/h.

For CRRT initiation, the circuit was primed with crossmatched blood mixed with NS and 5,000 units/L heparin to
hematocrit of 30%. High dose CRRT was prescribed, targeting
dialysate and replacement fluid flow rates of 8,000 ml/h/1.73
m2 vs. conventional dosing of only 2,000 ml/h/1.73 m2 , as
recommended for infants with hyperammonemia (6). The
CRRT was initiated using PrismasolTM solution containing
4 mEq/L of potassium and 32 mEq/L bicarbonate. At
initiation of CRRT, the patient did not have any worsening
of hemodynamic instability that required either escalation
of inotropic medications (i.e., epinephrine) s or addition of
alternative inotropes or vasopressors. Vital signs at the time
of initiation were: T35.5◦ C, HR 148, RR 42, BP 94/67, 96%
on FiO2 of 0.6. She tolerated a blood flow rate of 40 ml/min,
a dialysate flow rate of 1,400 ml/h, and a replacement fluid
rate of 200 ml/h. Anticoagulation was maintained with citrate
dextrose solution at 30 ml/h titrated for a goal circuit ionized
calcium of <0.5 mmol/L, which provided an anticoagulation
effect of aPTT 34–45 s (1.5–2.0 X normal). Electrolytes were
monitored at a minimum of every 4 h during high dose CRRT
due to risk of electrolyte imbalance. The patient did not have
any hypokalemia or worsening of hypothermia during her
circuit run; asymptomatic hypophosphatemia did occur and was
corrected with intravenous potassium phosphate infusions. After
10 h of CRRT, her ammonia level was <60 µg/dl and CRRT
was discontinued. Figure 1 demonstrates serial serum ammonia
levels and rate of ammonia clearance. Twelve hours after the
CRRT was discontinued the patient had a significant rebound of
serum ammonia level which required re-initiation of CRRT for
an additional 4 h. Scavenger therapy was maintained during the
peri-CRRT period for theoretical additive effect.

Technical Considerations
The CRRT circuit was primed with cross-matched blood
mixed with NS and 5,000 units/L heparin to hematocrit
of 30%. As previously recommended, high dose CRRT was
prescribed, targeting dialysate, and replacement fluid flow rates
of 8,000 ml/h/1.73m2 (6). The patient’s vitals at circuit initiation
were 36.9◦ C, HR 129, RR 32 (intubated, sedated, and on
neuromuscular blockade after the OR course), and BP 66/36.
With hemodynamic instability, he was given a bolus of calcium
gluconate 100 mg/kg. After initiation of CRRT using PrismasolTM
solution containing 4 and 32 mEq/L bicarbonate, the patient
tolerated a blood flow rate of 40 ml/min, a dialysate flow
rate of 1,400 ml/h, and a replacement flow rate of 200 ml/h.
Anticoagulation was maintained with citrate dextrose solution at
56 ml/h titrated for goal circuit ionized calcium of < 0.5 mmol/L.
Continuous renal replacement therapy was discontinued after
15 h once goal ammonia levels (<100 µg/dl) were achieved.
During his circuit run, he did not have any hypokalemia or
hypothermia. Figure 2 summarizes the patient’s serial serum
ammonia levels and rate of ammonia clearance.

Patient Outcome
Due to significant disease related neurologic dysfunction over
the 24 h post CRRT initiation, the family decided to redirect her
goals of care to comfort measures and the patient died the next
day. Her diagnostic postmortem work-up revealed a diagnosis
of citrullinemia.

Patient Outcome
The patient was discharged from the hospital with a new
diagnosis of methylmalonic acidemia.

Case B

DISCUSSION

Presentation

Hyperammonemia is a clinical finding with life-threatening and
life-altering implications. If left untreated, hyperammonemia
can lead to irreversible brain injury especially in the developing
brain. This injury may result in intractable seizures, motor
and/or cognitive impairment, cerebral palsy, and even death
(7). It is hypothesized that hyperammonemia causes irreversible
brain damage causally through its glutamine production
metabolic pathway. More specifically, in astrocytes ammonia is
converted into glutamine via the glutamine synthase enzyme.
In physiologic environments, this enzymatic pathway exists
at near capacity, making it easily saturated under increased
ammonia production. Glutamine is transported to extracellular
fluid via the SNAT5 transporters and is eventually taken up
by neighboring neurons where is enzymatically converted
to glutamate via glutaminase. Glutamate is then released

A 3 day old Caucasian male that presented to an outside hospital
and was noted to be “listless with poor feeding and tone.” In
initial assessment he was noted to be hypothermic at 32.5◦ C with
delayed capillary refill and a POC glucose of 1.89 mmol/L. He
was given 6 ml of d10 water with improvement in glucose to 3.39
mmol/L. He was fluid resuscitated for hypotension with 50 ml of
NS for a systolic blood pressure of 68 mmHg. Blood, urine, and
cerebrospinal fluid cultures were collected and he was started on
empiric antibiotics with ampicillin and gentamicin prior to ICU
transfer. Upon arrival to the ICU, his temperature was 36.7◦ C
with pulse 136, respiratory rate 60, and blood pressure of 71/26
via non-invasive automated sphygmomanometer. His physical
examination included a capillary refill <2 s, clear to auscultation
lung fields, no presence of cardiac murmurs, and a liver palpated
2 cm below the right costal margin. He demonstrated minimal
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FIGURE 1 | Serum ammonia levels from time of admission to resolution of hyperammonemia. Serum ammonia levels substantially decreased with the addition of
CRRT to pharmacologic scavenger therapies (AmmonulTM ). Although both therapies were effective in decreasing serum ammonia levels, it appears that CRRT
combined with AmmonulTM provides a more robust decrease. CRRT rate settings in both cases were: blood flow of 40 ml/min, dialysate flow of 1,400 ml/h, and
replacement flow of 200 ml/h.

FIGURE 2 | Rate of ammonia clearance from time of admission to resolution of hyperammonemia. This was determined as the slope between each proximal pair of
serum ammonia measurements. The rate of change is most significant with initial fluid resuscitation and then again with combination therapy of ammonium
scavengers and CRRT.

with UCDs between 1978 and 1995. By1995, the 5-year survival
rate was 22% for neonatal-onset and 41% for late-onset UCDs.
Among the 20 long-term survivors of the neonatal-onset UCDs,
90% (18/20) had moderate-to-severe neurodevelopmental
deficits compared to 28% (13/47) of patients with late-onset
development of UCDs. When analyzing 108 of these patients,
peak ammonia level during the first hyperammonemic attack was
correlated to neurodevelopmental outcome. Specifically, when
peak ammonia levels were <306 µg/dl (five times upper limit
of normal), there were no severe neurological deficits; however,
when peak ammonia levels were >596 µg/dl (10 times upper
limit of normal), patients either died or had severe neurological
deficits (10). The hypothesis that peak ammonia levels may have
a significant correlation with clinical outcome is also supported
by Claude Bachmann who performed a retrospective evaluation
on 88 patients with UCDs and found that when peak ammonia
levels were ≥817 µg/dl, none of the patients had a normal

into the synaptic cleft where it activates NDMA receptors
which leads to excito-toxicity. This NMDA-receptor activation
further potentiates increased intracranial pressure through the
activation of nitric-oxide synthetase which synthesizes nitric
oxide, a vasodilator (8). Additionally, glutamate is an osmotic
agent and is hypothesized to contribute to the cerebral edema
seen in patients with hyperammonemia. Furthermore, glutamine
in mitochondria is converted back into ammonia through
the phosphate-activated glutaminase. Ammonia is known to
increase mitochondrial permeability leading to mitochondrial
swelling and dysfunction, ultimately leading to cellular
death (9).
A thorough understanding of the pathophysiology of
hyperammonemia is crucial in improving the outcomes
associated with the hyperammonemia secondary to UCDs and
mitigating its consequences. In Japan, Uchino et al. investigated
the clinical outcome and prognosis of 216 patient diagnosed
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with IV fluids. There are several possible contributing factors
that may explain why Case A has a more significant
rebound of ammonia than Case B. One of these factors is
a delay in maintenance Ammonul initiation for Case A as a
result of a pharmaceutical error; this error underscores the
efficacy of ammonia scavengers in serum ammonia reduction.
However, in severe enzyme deficiencies and in cases of
severe hyperammonemia, medical therapy alone is often not
sufficiently quick or robust. Another possible confounder in
the rate of rebound between the two patients is their separate
enzyme deficiencies. Given their differing diagnoses, a direct
comparison of rebound hyperammonemia becomes difficult
to interpret.
Other case reports and series have also utilized CRRT, though
strategies have differed temporally to ammonia reduction. For
instance although largely different from our strategy, Kim et al.
utilized CRRT to reduce ammonia levels in a newborn with
ornithine transcarbamylase deficiency (OTC), a common UCD,
though they continued CRRT for 7 days while using blood flow
rates of 25 ml/min, with a replacement and dialysate rate both
at 150 ml/h. Additionally, this group did not utilize a scavenger
therapy. Using their strategy, the patient’s ammonia was reduced
from a peak of >1, to 422 µg/dl at 24 h, and 222 µg/dl at 57 h.
The patient had a rebound in ammonia 364 µg/dl after 5 days
of dialysis and therefore continued on CRRT until 7 days (15).
Another case series by Santa Maria et al. included six newborns
with UCDs who were placed on CRRT. Of these six, four were
placed on hemo-dialysis-filtration. The average length of time on
dialysis for all six patients was 49.5 h, a noticeable difference to
the timing required by the two patients in our study. In regards
to outcomes, two of the six patients died and only one of the four
survivors had neurological deficits at follow-up 2.3 years later
(16). Furthermore, our approach to CRRT therapy aligns with
Spinale et al. who presented two case reports of infants with OTC
presenting within 1 week of life with hyperammonemia (peak
ammonia levels of 2,475 and 2,362 µg/dl, respectively) where the
treatment team utilized CRRT with dialysate and replacement
fluid rates of 8,000 ml/h/1.73 m2 (four times higher than normal
dialysate/replacement fluid rates used in acute kidney injuries).
They found that the ammonia for both infants decreased to <681
µg/dl within 2 h, and <170 µg/dl within 10 h. Both infants had
mild rebound in ammonia levels to 254 and 283 µg/dl (with the
second infant having <170 µg/dl after 24 h of discontinuation of
CRRT) (6).
The use of CRRT therapy in <3 kg infants has some important
technical considerations. Care must be taken when initiating
CRRT for small infants as the circuit volume is a significant
percentage of their circulating blood volume. The extracorporeal
circuit used for both patients in this series was 72 ml. If an
estimated blood volume for this age range is 80 ml/kg, with
Patient A weighing 2.52 kg (body surface area of 0.19 m2 ) and
Patient B weighing 2.92 kg (body surface area of 0.20 m2 ), the
extracorporeal volume is 36 and 31%, respectively. Preparation
and prevention for impending hemodynamic instability when
initiating CRRT is necessary with the consideration and
use of inotropes in addition to priming the circuit with
diluted RBCs.

neurological outcome (11). In contrast, Msall et al., found in
26 patients with neonatal UCDs that there was no significant
correlation between peak ammonia levels and IQ, but rather a
significant negative linear correlation (r = −0.72, p < 0.001)
between the duration of a stage III or IV hyperammonemic coma
and IQ at 12 months of age (12). Though the clinical outcomes
of neonates with hyperammonemia secondary to UCDs would
benefit from larger retrospective analyses, the initial findings of
these studies all highlight the importance of timely diagnoses
and prompt reduction of ammonia levels.
In our case series, we describe two patients with similar
presentations of severe hyperammonemia, due to different
metabolic diseases, and differing outcomes. There are a number
of similarities and key differences in disease presentations
between both newborns. Both patients presented as small for
gestational age, within the first week of life, and with severe
dehydration. More specifically, Case A presented a day later than
Case B, which may explain the severity of her clinical course
including worsened initial acidosis and presenting ammonia level
more than twice that of Case B. Despite these differences, both
patients achieve rapid ammonia clearance. Figures 1, 2 both
show that when high dose hemo-dialysis-filtration is applied to
standard ammonia scavenging therapies, serum ammonia can
rapidly decline to normal levels in <24 h.
There are some additional differences between the presented
two cases including the use of Arginine administration in Case
A as compared to the decision to forego this therapy in Case
B. First, although neither patient had a diagnosis prior to
medical scavenger therapies, arginine therapy is not without
hypothetical risk i.e., if patient A had arginase deficiency,
then arginine would be contraindicated. However, given the
unlikely diagnosis of arginase deficiency with a severe clinical
presentation, particularly with such a high ammonia level,
incongruence with typical presentation later in life, and without
such profoundly high levels of ammonia, arginine was given in
patient A.
Additionally, both patients experience a rebound in ammonia
levels just discontinuation of CRRT. We postulate that the
scavenger therapies were not yet at steady state, potentially due
to the clearance of this therapy because of high dose CRRT and
the patients remained in a catabolic state causing an increase in
ammonia. Furthermore, aggressive alimentation was not pursued
during the period of CRRT; while both infants were started on
appropriate initial GIR fluids, neither were escalated on dextrose
containing fluids, started on lipid infusions, nor insulin infusions,
all of which are methods to prevent further catabolism. The
rebound phenomenon our patients experienced may be in part
because of the kidney replacement strategy. Ammonia has a
high volume of distribution, and therefore redistribution from
extravascular space occurs. As this is a recognized and expected
occurrence, some centers report using high-flux CRRT until
ammonia levels return to goal range, and then continuing regular
flow CRRT for another 12–24 h (13, 14). This case series adds
support to that strategy.
Figure 1 reinforces some key clinical pearls in the treatment of
hyperammonemia. Both patients have an initial improvement in
serum ammonia levels secondary to stabilization and rehydration
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Nonetheless, in this case-series, we show that CRRT
is technically feasible in low weight infants with severe
hyperammonemia secondary to inborn errors of metabolism.
Undeniably barriers to ammonia clearance are logistical and
primarily involve technical challenges associated with patient
access and hemodynamic instability—placement of a large
enough catheter to perform dialysis at high blood flow
rates as well as careful monitoring of hemodynamics given
the high ratio of extracorporeal volume to patient blood
volume. Further studies emphasizing earlier diagnosis and rapid
deployment of CRRT across centers will likely yield the greatest
improvements in morbidity and mortality for this patient
population. Additionally, future studies evaluating rapid CRRT
initiation for severe hyperammonemia secondary to inborn
errors of metabolism are needed to help clarify aspects of care
teasing out timing of initiation, cases that might be ammendale
to scavenger therapy alone, and prognostic factors of worsened
outcomes for this patient population.

Additionally, close monitoring for hypocalcemia is required.
High dialysate prescription rates based upon effluent dose can
result in total calcium depletion if calcium is not used in dialysate
replacement fluids—which was the case at the time these patients
received renal replacement therapy. Furthermore, this patient
population often presents in extremis with severe acidosis. As
this acidosis is corrected by care teams, these infants have a
calcium shift from extracellular space to intracellular space.
Finally, there is a high incidence of citrate toxicity in patients with
inborn errors of metabolism as a result of poor hepatic function
(both from hypo-perfusion as well as immaturity) which further
compounds the risk of hypocalcemia. Although we believe the
risk of citrate toxicity was low in these patients because citrate
is based upon blood flow (and not effluent rate) as well as
allowing for higher post filter ionized calcium levels, the risk of
hypocalcemia is high for the multitude of reasons detailed here.
Calcium and electrolyte levels need to be monitored frequently,
and both patients in this series needed boluses of calcium
gluconate on top of the calcium infusions given for reversal of
citrate anticoagulation.
Our case series has some limitations. Although 138 patients
diagnosed with hyperammonemia were screened for this study,
only two met inclusion criteria. The most likely explanation for
this is sampling bias from the retrospective nature of the study.
As a result, we are only able to make definitive conclusion on
the logistics of clearing ammonia in low birth weight infants via
CRRT as opposed to drawing conclusions on therapeutic efficacy.
For instance, despite adequate ammonia clearance, Patient A did
not have meaningful neurologic recovery, which we attribute to
both the severity of her enzyme deficiency and her significant
disease process at the time of presentation. In comparison,
the use of ammonia scavenging therapies in conjunction
with the use of CRRT rapidly decreased the ammonia levels
in Patient B who subsequently survived his hospitalization.
This difference in patient outcome is likely secondary
to differences in enzyme deficiency and severity of illness
at presentation.
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